Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Karla Madalin

Neurology Ravenna, OH Medical Doctor

NPI 1194786822 CMS profile 8572

6847 N Chestnut St Ste 325, Ravenna, OH 44266

Open in the dashboard

General payments

$4,031

144 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karla Madalin of Ravenna, OH is reported in the CMS Open Payments database as having received $4,031 across 144 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2023 General $116 5
2022 General $345 10
2021 General $846 28
2020 General $440 22
2019 General $2,270 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karla Madalin
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Karla Madalin were reported at $14. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Karla Madalin Neurology median Middle half National median
2019 $2,270 $474 $118–$2,177 $163
2020 $440 $367 $82–$2,309 $114
2021 $846 $438 $104–$2,547 $132
2022 $345 $442 $103–$2,388 $149
2023 $116 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $14 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $737 17 payments
  2. Novartis Pharmaceuticals Corporation $441 19 payments
  3. Genzyme Corporation $436 10 payments
  4. Alexion Pharmaceuticals, Inc. $276 5 payments
  5. Teva Pharmaceuticals USA, Inc. $230 9 payments
  6. E.R. Squibb & Sons, L.L.C. $219 3 payments
  7. US WorldMeds, LLC $160 5 payments
  8. Genentech USA, Inc. $148 4 payments
  9. SK Life Science, Inc. $137 2 payments
  10. UCB, Inc. $132 6 payments
  11. Other $1,114 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,953 136 payments
  2. Education $63 7 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16 1 payment
Products named General payments · program years 2019–2025
  1. AUBAGIO Multiple Sclerosis $267 5 payments
  2. VUMERITY $246 3 payments
  3. ZEPOSIA $240 4 payments
  4. AUBAGIO Neurology $170 5 payments
  5. APOKYN $160 5 payments
  6. AIMOVIG $153 8 payments
  7. TECFIDERA $137 10 payments
  8. Briviact $132 6 payments
  9. AUSTEDO $122 1 payment
  10. XCOPRI $116 1 payment
  11. Other $1,872 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$3,388

Medicare's payments for the services billed

Medicare patients

26

Average age 78

Services billed

38

14 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 58%
Diabetes 50%
Heart failure 50%
Chronic kidney disease 50%
Atrial fibrillation 46%
Depression 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

144 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record